CTCs as a biomarker of tumor burden in multiple myeloma

Circulating tumor DNA as a biomarker in multiple myeloma: pitfalls and future outlooksПодробнее

Current & emerging biomarkers in multiple myelomaПодробнее

CTCs in myeloma: egression mechanisms, transcriptomics, and prognostic valueПодробнее

Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24Подробнее

RNA profiling of circulating tumor cells in myeloma patientsПодробнее

The value of CTCs and cfDNA as novel biomarkers in multiple myelomaПодробнее

Circulating tumor cell burden as a component of staging in multiple myelomaПодробнее

Unveiling Novel Biomarkers in Myeloma: The Role of CTCs & cfDNA | Bruno Paiva, PhD | IMS 2024Подробнее

Could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in MM?Подробнее

Ultrastratification of multiple myeloma via biomarkersПодробнее

50 Minutes on MULTIPLE MYELOMAПодробнее

SWIFT-Seq: single-cell RNA sequencing of CTCs for patients with multiple myeloma and precursorsПодробнее

Circulating tumor cells in multiple myelomaПодробнее

The value of circulating tumor cells for the staging of patients with NDMMПодробнее

Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma CohortПодробнее

CTC enumeration as a prognostic biomarker in prostate cancerПодробнее

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible MMПодробнее

Novel strategies to evaluate biomarkers of interest in multiple myelomaПодробнее

Predicting MRD outcomes in myeloma using machine learningПодробнее